Pharmaceutical Companies Raise Health Service Sponsorship to €58m
Pharmaceutical companies spent €58.5m sponsoring doctors, patients organisations and healthcare providers last year, the Volkskrant said on Thursday.
This is a rise of 13% on 2015, the paper said, quoting figures from the Transparantieregister Zorg, set up five years ago to provide details about healthcare sponsorship.
Most of the increase is due to extra spending on care institutions and doctors. Payment to patients organisations fell by €500,000 to €1.7m. Less money also went to pay doctors to speak at conferences, a trend which first began in Britain with GlaxoSmithKline.
Sponsoring by pharmaceutical companies is controversial because it can give rise to conflicts of interest. ‘Companies are not paying €58m in order to get nothing back. They are not philanthropists,’ said Ruud Coolen van Brakel of the IVM institute which investigates prescription patterns.
‘The sponsor cash paid to patients organisations is recouped in the price of medicines,’ he said. ‘No-one asks if we all benefit from this.’
2026-10-17
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
VIV Health & Nutrition Asia 2026 Brings Together Innovation and Business Across the Animal Feed and Health Industry
-
Two Types Of Progesterone Only Pill That Commonly Used
-
Pharmaceutical and Health Industry Special Study - The Arrival of New Opportunities
-
Four Foods that can Protect Your Heart Health
-
Selling Expired Food, Losing Money And Being Fined
-
Blood Pressure Control in Elderly Patients with Hypertension
-
The Valve Track Has Multiple Layouts, and the R&D Innovation Heat is Rising
-
Brief Intriduction of the Free Radicals in Human Body
-
CPHI CHINA 2021
-
Hi & Fi Asia-China Expo 2020
Recommend Reading
-
Iran's Only MDI/TDI Plant Attacked, Middle East Supply Nearly Zero, Global Gap Widens
-
Japan Begins Construction of the World’s Largest Commercial Liquid Hydrogen Receiving Terminal
-
Arkema's New Singapore Plant Commences Operations, Tripling Polyamide Capacity
-
Rare Earth and Power: Strategic Probing Beneath the New U.S.–China Trade Framework
-
Lupin Secures Tentative U.S. Approval for Its Multiple Sclerosis Tablet
-
Business Society’s Market Outlook for Natural Rubber on September 17, 2026: Volatile Consolidation
-
Business Society’s Market Outlook for Butadiene Rubber on September 17, 2026: Short-Term Upside Potential Is Limited
-
Business Society’s ABS Market Outlook on September 17, 2026: Clearly Downward
-
Rate of Change Remains Negative, Leading to Another Retail Price Cut for Refined Oil Products This Round
-
Business Society September 17, 2026 MIBK Trend Analysis: Moderate Correction